Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.84 AUD | +0.35% | +1.07% | -35.45% |
05-01 | Nanosonics Submits De Novo Application to US FDA for CORIS Cleaning Technology | MT |
03-15 | Nanosonics Chief Technology Officer to Retire | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an expected P/E ratio at 97.63 and 63.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.42 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-35.45% | 557M | B+ | ||
+7.56% | 219B | B | ||
+6.41% | 183B | B- | ||
+11.88% | 132B | B- | ||
+24.47% | 106B | A- | ||
-2.66% | 62.09B | A- | ||
+4.81% | 50.88B | B+ | ||
+11.32% | 50.8B | B+ | ||
-1.30% | 40.64B | A | ||
+26.46% | 31.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NAN Stock
- Ratings Nanosonics Limited